Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock

BioMarin Pharmaceutical (BMRN) is highlighted by Zacks as a strong growth stock, despite holding a #3 (Hold) Zacks Rank, due to its 'A' VGM Score and 'B' Growth Style Score. The company is projected to achieve 25.9% year-over-year earnings growth for the current fiscal year, further bolstered by 12 analysts raising fiscal 2025 estimates, which increased the consensus by $0.16 to $4.43 per share. With an average earnings surprise of +25.7%, BMRN's robust growth indicators suggest it warrants investor consideration.

Analysis

BioMarin Pharmaceutical (BMRN) presents a mixed but compelling profile for growth-focused investors, according to Zacks' proprietary metrics. Despite a neutral Zacks Rank of #3 (Hold), the company exhibits strong underlying growth indicators, meriting a top-tier VGM Score of 'A' and a 'B' for its Growth Style Score. The primary driver is a significant forecasted year-over-year earnings growth of 25.9% for the current fiscal year. This forward-looking optimism is reinforced by positive analyst sentiment, with 12 analysts revising their fiscal 2025 earnings estimates upward in the last 60 days, pushing the consensus estimate to $4.43 per share. Furthermore, BMRN has a history of outperformance, demonstrated by an average earnings surprise of +25.7%, suggesting a consistent ability to exceed market expectations.

Key Decisions for Investors

• Given the strong projected earnings growth of 25.9% and positive fiscal 2025 estimate revisions, growth-oriented investors might find BMRN attractive, particularly noting its track record of substantial earnings beats.
• Investors should exercise caution and investigate the factors contributing to the neutral #3 (Hold) rating, as it may reflect valuation concerns or other risks not detailed in the article that temper the bullish growth outlook.
• Consider placing BMRN on a watchlist, as a potential upgrade in its Zacks Rank from 'Hold' to 'Buy' would create a more powerful bullish signal when combined with its existing high-grade growth and VGM scores.